- CancerNetwork.com
- CureToday.com
- OncLive.com
- TargetedOnc.com
- Privacy
- Terms & Conditions
- Do Not Sell My Information
© 2022 MJH Life Sciences™ and Oncology Nursing News. All rights reserved.
Lee Greenberger on Newly Approved Drugs for Multiple Myeloma
Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses new agents that were recently approved for multiple myeloma.
Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses new agents that were recently approved for multiple myeloma.
Three drugs were FDA approved within 3 weeks — Darzalex (daratumumab), Ninlaro (ixazomib), and Empliciti (elotuzumab). Darzalex and Empliciti are antibodies, and Ninlaro is a proteasome inhibitor.
The agents can be used as monotherapy or in combination with conventional therapy, Greenberger explains. They have also extended progression-free survival in patients with myeloma.
